IBDEI0F5 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7286,0)
 ;;=379.24^^49^556^105
 ;;^UTILITY(U,$J,358.3,7286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7286,1,3,0)
 ;;=3^Vitreous Floaters
 ;;^UTILITY(U,$J,358.3,7286,1,4,0)
 ;;=4^379.24
 ;;^UTILITY(U,$J,358.3,7286,2)
 ;;=Vitreous Floaters^88242
 ;;^UTILITY(U,$J,358.3,7287,0)
 ;;=379.26^^49^556^107
 ;;^UTILITY(U,$J,358.3,7287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7287,1,3,0)
 ;;=3^Vitreous Prolapse
 ;;^UTILITY(U,$J,358.3,7287,1,4,0)
 ;;=4^379.26
 ;;^UTILITY(U,$J,358.3,7287,2)
 ;;=Vitreous Prolapse^269312
 ;;^UTILITY(U,$J,358.3,7288,0)
 ;;=379.23^^49^556^106
 ;;^UTILITY(U,$J,358.3,7288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7288,1,3,0)
 ;;=3^Vitreous Hemorrhage
 ;;^UTILITY(U,$J,358.3,7288,1,4,0)
 ;;=4^379.23
 ;;^UTILITY(U,$J,358.3,7288,2)
 ;;=Vitreous Hemorrhage^127096
 ;;^UTILITY(U,$J,358.3,7289,0)
 ;;=362.18^^49^556^89
 ;;^UTILITY(U,$J,358.3,7289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7289,1,3,0)
 ;;=3^Retinal Vasculitis
 ;;^UTILITY(U,$J,358.3,7289,1,4,0)
 ;;=4^362.18
 ;;^UTILITY(U,$J,358.3,7289,2)
 ;;=Retinal Vasculitis^264463
 ;;^UTILITY(U,$J,358.3,7290,0)
 ;;=360.21^^49^556^31
 ;;^UTILITY(U,$J,358.3,7290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7290,1,3,0)
 ;;=3^Degenerative Myopia
 ;;^UTILITY(U,$J,358.3,7290,1,4,0)
 ;;=4^360.21
 ;;^UTILITY(U,$J,358.3,7290,2)
 ;;=Degenerative Myopia^268553
 ;;^UTILITY(U,$J,358.3,7291,0)
 ;;=362.64^^49^556^80
 ;;^UTILITY(U,$J,358.3,7291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7291,1,3,0)
 ;;=3^Reticular Degeneration
 ;;^UTILITY(U,$J,358.3,7291,1,4,0)
 ;;=4^362.64
 ;;^UTILITY(U,$J,358.3,7291,2)
 ;;=Reticular Degeneration^268645
 ;;^UTILITY(U,$J,358.3,7292,0)
 ;;=362.61^^49^556^29
 ;;^UTILITY(U,$J,358.3,7292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7292,1,3,0)
 ;;=3^Degeneration, Paving Stone
 ;;^UTILITY(U,$J,358.3,7292,1,4,0)
 ;;=4^362.61
 ;;^UTILITY(U,$J,358.3,7292,2)
 ;;=Paving Stone Degeneration^268642
 ;;^UTILITY(U,$J,358.3,7293,0)
 ;;=362.42^^49^556^94
 ;;^UTILITY(U,$J,358.3,7293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7293,1,3,0)
 ;;=3^Rpe Detachment, Serous
 ;;^UTILITY(U,$J,358.3,7293,1,4,0)
 ;;=4^362.42
 ;;^UTILITY(U,$J,358.3,7293,2)
 ;;=Serous RPE Detachment^268633
 ;;^UTILITY(U,$J,358.3,7294,0)
 ;;=362.43^^49^556^93
 ;;^UTILITY(U,$J,358.3,7294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7294,1,3,0)
 ;;=3^Rpe Detachment, Hemorrhagic
 ;;^UTILITY(U,$J,358.3,7294,1,4,0)
 ;;=4^362.43
 ;;^UTILITY(U,$J,358.3,7294,2)
 ;;=Hemorrhagic RPE Detachment^268634
 ;;^UTILITY(U,$J,358.3,7295,0)
 ;;=250.00^^49^556^34
 ;;^UTILITY(U,$J,358.3,7295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7295,1,3,0)
 ;;=3^Dm Type II, No Retinopathy
 ;;^UTILITY(U,$J,358.3,7295,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,7295,2)
 ;;=DM Type II, No Retinopathy^33605
 ;;^UTILITY(U,$J,358.3,7296,0)
 ;;=250.01^^49^556^33
 ;;^UTILITY(U,$J,358.3,7296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7296,1,3,0)
 ;;=3^Dm Type I, No Retinopathy
 ;;^UTILITY(U,$J,358.3,7296,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,7296,2)
 ;;=DM Type I, No Retinopathy^33586
 ;;^UTILITY(U,$J,358.3,7297,0)
 ;;=250.50^^49^556^25
 ;;^UTILITY(U,$J,358.3,7297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7297,1,3,0)
 ;;=3^Csme In DM Type II
 ;;^UTILITY(U,$J,358.3,7297,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,7297,2)
 ;;=CSME in DM type II^267839^362.83
 ;;^UTILITY(U,$J,358.3,7298,0)
 ;;=250.51^^49^556^27
 ;;^UTILITY(U,$J,358.3,7298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7298,1,3,0)
 ;;=3^DM Type I w/ Ophtharlmic Manifestation
 ;;^UTILITY(U,$J,358.3,7298,1,4,0)
 ;;=4^250.51
